TRT After TRAVERSE: What the Heart-Safety Study Actually Says

For most of the last decade, any honest conversation about testosterone therapy had to include a shrug about the heart. Early signals had raised the possibility that treatment might raise cardiovascular risk, the evidence was thin and conflicting, and a boxed warning hung over the whole category. Men asked a fair question, “is this going to hurt my heart,” and the truthful answer was “we don’t really know.”

In 2023 that changed. A large randomized trial called TRAVERSE was designed specifically to answer the cardiovascular question, and it is now the most solid evidence we have. It is worth understanding what it found, because the conclusion is neither “testosterone is dangerous” nor “testosterone is finally proven safe for everyone.” It is more precise, and more useful, than either headline.

What men are hearing

Two stories circulate, and both overshoot. One says testosterone causes heart attacks, a holdover from the older, weaker data. The other, now common in direct-to-consumer marketing, says the worry has been debunked and testosterone is simply safe. The actual finding sits between them, and the space between them is where careful care happens.

What TRAVERSE actually found

TRAVERSE enrolled more than five thousand men, aged 45 to 80, who had symptoms of low testosterone, confirmed low levels on testing, and either established cardiovascular disease or a high risk of it. Half received testosterone gel, half a placebo, and they were followed for an average of about three years.

On the central question, the result was reassuring. Major cardiac events, a composite of cardiovascular death, heart attack, and stroke, occurred in 7.0 percent of the testosterone group and 7.3 percent of the placebo group: statistically no worse than placebo. In a population already at high cardiovascular risk, treatment did not raise the rate of the events everyone had feared.

The fine print is where the judgment lives. The testosterone group had a higher incidence of three things: atrial fibrillation, an irregular heart rhythm; acute kidney injury; and pulmonary embolism, a clot in the lungs. These are not nothing. They are exactly the sort of risks a prescribing physician should be watching for, and exactly the sort a one-click service has no mechanism to catch.

What the study does not say

It does not say testosterone is risk-free. The clot and rhythm signals are real and warrant monitoring.

It does not say testosterone helps the heart. This was a safety study, not a study showing cardiovascular benefit.

And it does not apply to everyone taking testosterone. TRAVERSE studied men with genuine, symptomatic, lab-confirmed low testosterone, treated to a normal range under supervision. It says nothing reassuring about high doses chased for performance, or about men who never had a deficiency in the first place.

What changed at the FDA

In early 2025 the FDA updated the labeling across testosterone products to match the better evidence: it removed the older boxed warning about cardiovascular risk, while adding a caution that testosterone can raise blood pressure. That is the same shape as the trial, reassurance on the main question, specific new cautions to manage, not a blanket all-clear.

What a careful physician does with this

The trial makes thoughtful treatment easier to justify; it does not make casual treatment safe. Good practice still means confirming a genuine deficiency before starting, and then monitoring the things this evidence flags: blood pressure, the red-blood-cell count testosterone can push up, prostate health appropriate to age, and any signs of an irregular rhythm or clotting. The reassurance from TRAVERSE is earned by doing the monitoring it implies, not by skipping it.

What not to assume

Don’t assume the old “testosterone wrecks your heart” warning still stands. For appropriately selected men, the best evidence did not find higher rates of major cardiac events.

Don’t assume that means testosterone is simply safe, or good for the heart. The trial found specific risks to watch, and showed benefit on neither.

And don’t assume a study done in carefully selected, monitored men justifies an unmonitored prescription from a form you filled out at night. The finding that should travel with you is narrow and real: in the right man, properly evaluated and followed, testosterone did not raise the cardiovascular risk that worried everyone, and it still deserves a physician who is watching.

This article is educational and is not medical advice or a promise of results. Whether testosterone therapy is appropriate, and how it is monitored, is individual and physician-directed, based on your own history and laboratory testing.